2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19000
    ACC-9358 90446-66-5 98%
    ACC-9358 is an orally active sodium channel blocker. ACC-9358 has antiarrhythmic activity. ACC-9358 can be used in research on cardiovascular diseases such as arrhythmias.
    ACC-9358
  • HY-19003
    Isomazole 86315-52-8 98%
    Isomazole is a new cardiotonic agent. Isomazole increases the calcium sensitivity in atrial fibers and has a direct effect on contractile proteins.
    Isomazole
  • HY-19004
    711389-S hydrochloride 94899-83-9 98%
    711389-S hydrochloride is an antiarrhythmic compound that demonstrates its antiarrhythmic activity by increasing the ventricular fibrillation threshold (VFT). 711389-S hydrochloride also has strong anti-fibrillation effects and safety, and can be used in the study of ventricular fibrillation and sudden cardiac death. 711389-S hydrochloride also inhibits the sodium current.
    711389-S hydrochloride
  • HY-19012
    N-1518 93750-14-2 98%
    N-1518 is an α and β adrenergic receptor blocker that has competitive antagonism against β1 and α1 receptors, but does not show selectivity for β1 receptors, but shows about 20-fold selectivity for α1 receptors. N-1518 has vasodilatory effects and can be used in the research field of hypertension treatment.
    N-1518
  • HY-19013
    L 44-0 95240-93-0 98%
    L44-0 is a nicotinic acid derivative. L44-0 reduces atherosclerotic lesions and decreases vascular norepinephrine levels in the renal arteries, femoral arteries, and veins in a New Zealand white rabbit model of atherosclerosis. L44-0 can be used in research on cardiovascular and cerebrovascular diseases such as atherosclerosis.
    L 44-0
  • HY-19020
    FK-664 94936-90-0 98%
    FK-664 is a leukotriene inhibitor. FK-664 enhances ventricular contractility and shortens the time to peak tension in cardiac cells. FK-664 reduces mean circulating pressure (MCP) in a canine model of heart failure. FK-664 can be used in research on cardiovascular diseases such as heart failure.
    FK-664
  • HY-19022
    BW A256C 98410-36-7 98%
    Palatrigine is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties.
    BW A256C
  • HY-19035
    DN-9693 dihydrochloride 96086-68-9 98%
    DN-9693 dihydrochloride is a phosphodiesterase inhibitor with a platelet membrane effect. DN-9693 dihydrochloride can increase platelet cyclic AMP and inhibit ristocetin-induced platelet agglutination and adhesion.
    DN-9693 dihydrochloride
  • HY-19037
    SM-2470 99899-45-3 98%
    SM-2470 is a potent α1-adrenoceptor antagonist, has sympathetic nerve activity in anesthetized rats. SM-2470 is an antihypertensive agent. SM-2470 exhibits hypocholesterolaemic effect by the inhibition of cholesterol absorption related to the reduction of cholesterol solubilization.
    SM-2470
  • HY-19038
    Y-20487 103969-58-0 98%
    Y-20487 is a cardiotonic agent. Y-20487 can induce cyclic AMP accumulation and exhibit positive inotropy.
    Y-20487
  • HY-19039
    Y-20811 sodium 104363-98-6 98%
    Y-20811 sodium is a selective and orally active thromboxane synthetase inhibitor. Y-20811 sodium can irreversibly inhibit thromboxane (TX) A2 synthesis. Y-20811 sodium can be used for the research of cardiovascular disease, such as thrombosis.
    Y-20811 sodium
  • HY-19044
    SKF 95601 103949-62-8 98%
    SKF 95601 is a modulator of small conductive Ca2+-activated K+ channels with anti-atrial fibrillation (AF) activity. SKF 95601 may play a role in inhibiting atrial fibrillation by affecting the interaction between intracellular Ca2+ concentration and membrane potential. SKF 95601 has become a potential inhibitory target against atrial fibrillation due to its significant expression in various species, especially human atria.
    SKF 95601
  • HY-19049
    CK-1649 chloride 125883-03-6 98%
    CK-1649 chloride is a class III antiarrhythmic agent. CK-1649 chloride can inhibit potassium channel activity.
    CK-1649 chloride
  • HY-19052
    Trombodipine 113658-85-8 98%
    Trombodipine is an antithrombotic agent, inhibiting platelet aggregation.
    Trombodipine
  • HY-19057
    Vatinoxan 114914-42-0 99.83%
    Vatinoxan (MK-467) is an alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia.
    Vatinoxan
  • HY-19064
    CV-6504 117574-40-0 98%
    CV-6504 is a dual inhibitor of TXA2 synthase and 5-lipoxygenase. CV-6504 can scavenge ROS and exhibit antitumor activity. CV-6504 can be used for the researches of cancer, inflammation and cardiovascular disease.
    CV-6504
  • HY-19066
    KW-3407 115750-37-3 98%
    KW-3407 is an antiarrhythmic agent. KW-3407 can inhibit two-stage (24 and 48 h) coronary ligation-, digitalis- and adrenaline-induced spontaneously occurring arrhythmias with IC50 values of 18.1, 14.4, 18.3 and 21.4 μg/mL. KW-3407 can decrease the sinoatrial rate and contractile force, and increase the coronary blood flow and AV conduction times.
    KW-3407
  • HY-19070
    BRL-52656 115642-84-7 98%
    BRL-52656 is a blood-brain barrier (BBB)-penetrable KOR receptor agonist that exhibits a biphasic effect. At low doses, BRL-52656 decreases blood pressure, whereas high doses have the opposite effect in spontaneously hypertensive rats. Additionally, BRL-52656 induces water diuresis by inhibiting the secretion of vasopressin (AVP).
    BRL-52656
  • HY-19072
    BRL-36378 84768-09-2 98%
    BRL-36378 is an ACE inhibitor that inhibits angiotensin-converting enzyme activity. BRL-36378 can be used in ligand-based virtual screening to identify new leading structures for chemical optimization.
    BRL-36378
  • HY-19078
    SQ-30741 107332-47-8 98%
    SQ-30741 is a thromboxane A2 receptor antagonist. SQ-30741 reduces vasoconstriction in a feline pulmonary vascular bed model. SQ-30741 increases relaxation of aortic endothelium and vascular smooth muscle in adult rats in a spontaneously hypertensive rat model. SQ-30741 can be used in research on cardiovascular diseases such as hypertension.
    SQ-30741
Cat. No. Product Name / Synonyms Application Reactivity